Академический Документы
Профессиональный Документы
Культура Документы
Ácido valpróico
Jorge Téllez-Vargas, MD
232 J. Téllez-Vargas
Trastorno Bipolar
FARMACOCINÉTICA
Absorción y biodisponibilidad
Distribución
Metabolismo
234 J. Téllez-Vargas
Trastorno Bipolar
Eliminación
MECANISMO DE ACCIÓN
236 J. Téllez-Vargas
Trastorno Bipolar
238 J. Téllez-Vargas
Trastorno Bipolar
240 J. Téllez-Vargas
Trastorno Bipolar
Depresión bipolar
Ciclado rápido
Tolerancia
NEUROPROTECCIÓN
242 J. Téllez-Vargas
Trastorno Bipolar
Monitoreo médico
Dosis
Valproemia
EFECTOS SECUNDARIOS
244 J. Téllez-Vargas
Trastorno Bipolar
TABLA 1
Abordaje clínico de los efectos indeseables del ácido valpróico
INTERACCIONES MEDICAMENTOSAS
246 J. Téllez-Vargas
Trastorno Bipolar
248 J. Téllez-Vargas
Trastorno Bipolar
COMPLICACIONES
TERATOGÉNESIS
250 J. Téllez-Vargas
Trastorno Bipolar
SOBREDOSIS / INTOXICACIÓN
TABLA 2
Manejo de la sobredosis de ácido valpróico
252 J. Téllez-Vargas
Trastorno Bipolar
En adultos mayores
En el embarazo
REFERENCIAS
Arnsten AFT, Manji HK. Mania: a rational neurobiology. Future Neurol 3(2):125-
131, 2008.
Asghari V, Wang JF, Reiach JS, Young LT. Differential effects of mood stabilizers
on Fos/Jun proteins and AP-1 DNA binding activity in human
neuroblastoma SH-SY5Y cells. Brain Res 58:95-102, 1998.
Azorin JM, Findling RL. Valproate use in children and adolescents with bipolar
disorder. CNS Drugs 21(12):1019-33, 2007.
Bijur GN, Jope RS. Opposing Actions of Phosphatidylinositol 3-Kinase and Glycgen
Synthase Kinase - 3β in the regulation of HSF – 1 Ativity. J Neurochem
74:2401-2408, 2000.
Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, et al. Efficacy
of divalproex vs lithium and placebo in the treatment of mania. The
Depakote Mania Study Group. JAMA 271(12):918-24, 1994.
Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, et al. A rondomized,
placebo-controlled 12-month trial of divalproex and lithium in treatment
of aoutpatients with bipolar I disorder. Divalproex Maintenance Study
Group. Arch Gen Psychiatry 57(5):481-9, 2000.
Boyle WJ., Smeal T., Defize H., et al. Activation of Protein Kinase C Decreases
Phosphorylation of –Jun at Sites Tha Negatively Regulate its DNA Binding
Activity. Cell 64:573-584, 199.1
Calabrese JR, Woyshville MJ, Kimmel SE, Rapport DJ. Predictors of valproate
response in bipolar rapid-cycling. J Clin Psychopharmacol 13:280-
283, 1993.
Carvey PM. Drug Action in the Central Nervous System. Oxford University
Press, Oxford 203-206, 1998.
254 J. Téllez-Vargas
Trastorno Bipolar
Chen G, Huang LD, Jiang YM, Manji HK. The mood stabilizing agent valproate
inhibits the activity of glycogen synthase kinase-3. J Neurochem
72:1327-30, 1999. En: G, Manji HK, Hawver DB, Wright CB, Potter WZ.
Chronic sodium valproate selectively decreases protein kinase C alpha
and epsilon in vitro. J Neurochem 63:2361-4, 1994.
Chen G, Yuan PX, Jiang Y, Huang LD, Manji HK. Lithium increases tyrosine
hydroxylase levels both in vivo and in vitro. J Neurochem 70:1768-71,
1998.
Collins RM, Zielke HR, Woody RC. Valproate increases gultaminase and decrease
glutamine synthetase activities in primarty cultures of rqat brain
astrocytes. J Neurochem 6:1137-1143, 1994.
Drevets WC, Price JL, Simpson JR, Todd RD, Reich T, Vannier M, Raichle ME.
Subgenual prefrontal cortex abnormalities in mood disorders. Nature
38:824-7, 1997.
Evans RJ, Miranda RN, Jordan J, Krolikowski FJ. Fatal acute pancreatitis
caused by valproic acid. Am J Forensic Med Pathol 16(1):62-5, 1995
Fatemi SH, Stary JM, Earle JA, Araghi-Nikman M, Eagan E. GABAergic dysfunction
in schizophrenia and mood disorders as reflected levels of glutamic
decarboxilase 65 and 67 kDA and reeling proteins in cerebellum.
Schizophr Res 72:109-122, 2005.
Findling RL, Frazier TW, Youngstrom EA, McNamara NK, et al. Double-blind,
placebo-controlled trial of divalproex monotherapy in the treatment of
symptomatic youth at high risk for developing bipolar disorder. J Clin
Psychiatry 68(5):781-8, 2007.
Hahn CG, Umapathy , Wang HY, Koneru R, Levinson DF, Friedman E. Lithium
and valproic acid treatments reduce PKC activation and receptor-G
protein coupling in platelets of bipolar manic patients. J Psychiatr
Res. Jul;39(4):355-63, 2005.
Houghton BL, Bowers JB. Valproic acid overdose: a case report and review of
therapy. Med Gen Med 14(1):5-8, 2003.
Isojarvi JI, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and
hyperandrogenismoin women taking valproate for epilepsy. N Engl J
Med 328:1383-1388, 1993.
Lucas FR, Goold RG, Gordon-Weeks PR, Salinas PC. Inhibition of GSK-3-beta
leading to the loss of phosphorylated MAP-1B is an early event in
axonal remodelling induced by WNT-7a or lithium. J Cell Sci 111:1351-
61, 1998.
Manji HK, Bebchuk JM, Moore GL, Glitz D, Hasanat K, Chen G. Modulation of
CNS signal transduction pathways and gene expression by mood
stabilizing agents: therapeutics implications. J Clin Psychiatry 60(suppl
2):27-39, 1999.
256 J. Téllez-Vargas
Trastorno Bipolar
Manji HK, Lenox RH. Long-term action of lithium: a role for transcriptional
and postranscriptional factors regulated by protein kinase C. Synapse
16:11-28, 1994.
Manji HK, Lenox RH. The nature of bipolar disorder. J Clin Psychiatry 6 (suppl
13): 42-57, 2000.
McElroy SL, Klerk P. Antiepileptic drugs. En: The American Psychiatric Press
Texbook of Psychopharmacology. Schatzberg A, Nemeroff C. (eds),
Washington DC, American Psychiatric Press Inc, 1995.
McElroy SL, Klerk PE, Stanton SP, Tugrul KC, Bennet JA, et al. A randomized
comparison of divalproex oral loading versus haloperidol in the inicial
treatment of acute psychotic mania. J Clin Psychiatry 57:142-146,
1996.
Montezinho LP, Mork A, Duarte CB, Penachuck S, Geraldes CF, Castro MM.
Effects of mood stabilizers on the inhibition of adenylate cyclase via
dopamine D(2)-like receptors. Bipolar Disord 9(3):290-97, 2007.
Silva H. Mecanismos de acción de los estabilizadores del ánimo. Rev Chil Neuro-
Psiquiat 39(3):219-230, 2001.
Stambolic V, Ruel LR, Woodgett Jr. Lithium inhibits glycogen synthase kinase-
3 activity and mimic wingless signaling in intact cells. Curr Biol 6:1664-
8, 1996.
Tohen M, Ketter TA, Zarate CA, Suppes T, Frye M, et al. Olanzapine versus
divalproex sodium for the treatment of acute mania and maintenance
of remission: a 47 week study. Am J Psychiatry 160(7):1263-71, 2003.
258 J. Téllez-Vargas